1
|
Brochu HN, Song K, Zhang Q, Zeng Q, Shafi A, Robinson M, Humphrey J, Croy B, Peavy L, Perera M, Parker S, Pruitt J, Munroe J, Ghatti R, Urban TJ, Harris AB, Alfego D, Norvell B, Levandoski M, Krueger B, Williams JD, Boles D, Nye MB, Dale SE, Sapeta M, Petropoulos CJ, Meltzer J, Eisenberg M, Cohen O, Letovsky S, Iyer LK. A program for real-time surveillance of SARS-CoV-2 genetics. Sci Rep 2024; 14:20249. [PMID: 39215120 PMCID: PMC11364650 DOI: 10.1038/s41598-024-70697-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2024] [Accepted: 08/20/2024] [Indexed: 09/04/2024] Open
Abstract
The COVID-19 pandemic brought forth an urgent need for widespread genomic surveillance for rapid detection and monitoring of emerging SARS-CoV-2 variants. It necessitated design, development, and deployment of a nationwide infrastructure designed for sequestration, consolidation, and characterization of patient samples that disseminates de-identified information to public authorities in tight turnaround times. Here, we describe our development of such an infrastructure, which sequenced 594,832 high coverage SARS-CoV-2 genomes from isolates we collected in the United States (U.S.) from March 13th 2020 to July 3rd 2023. Our sequencing protocol ('Virseq') utilizes wet and dry lab procedures to generate mutation-resistant sequencing of the entire SARS-CoV-2 genome, capturing all major lineages. We also characterize 379 clinically relevant SARS-CoV-2 multi-strain co-infections and ensure robust detection of emerging lineages via simulation. The modular infrastructure, sequencing, and analysis capabilities we describe support the U.S. Centers for Disease Control and Prevention national surveillance program and serve as a model for rapid response to emerging pandemics at a national scale.
Collapse
Affiliation(s)
- Hayden N Brochu
- Labcorp Center for Excellence in Data Science, AI and Bioinformatics, Burlington, NC, 27215, USA
| | - Kuncheng Song
- Labcorp Center for Excellence in Data Science, AI and Bioinformatics, Burlington, NC, 27215, USA
| | - Qimin Zhang
- Labcorp Center for Excellence in Data Science, AI and Bioinformatics, Burlington, NC, 27215, USA
| | - Qiandong Zeng
- Labcorp Center for Excellence in Data Science, AI and Bioinformatics, Burlington, NC, 27215, USA
| | - Adib Shafi
- Labcorp Center for Excellence in Data Science, AI and Bioinformatics, Burlington, NC, 27215, USA
| | - Matthew Robinson
- Labcorp Center for Excellence in Data Science, AI and Bioinformatics, Burlington, NC, 27215, USA
| | - Jake Humphrey
- Labcorp Center for Excellence in Data Science, AI and Bioinformatics, Burlington, NC, 27215, USA
| | - Bobbi Croy
- Labcorp Information Technology, Burlington, NC, 27215, USA
| | - Lydia Peavy
- Labcorp Research and Development, Burlington, NC, 27215, USA
| | - Minoli Perera
- Labcorp Research and Development, Burlington, NC, 27215, USA
| | - Scott Parker
- Labcorp Research and Development, Burlington, NC, 27215, USA
| | - John Pruitt
- Labcorp Research and Development, Burlington, NC, 27215, USA
| | - Jason Munroe
- Labcorp Consumer Genetics Department, Burlington, NC, 27215, USA
| | | | - Thomas J Urban
- Labcorp Research and Development, Burlington, NC, 27215, USA
| | - Ayla B Harris
- Labcorp Research and Development, Burlington, NC, 27215, USA
| | - David Alfego
- Labcorp Center for Excellence in Data Science, AI and Bioinformatics, Burlington, NC, 27215, USA
| | - Brian Norvell
- Labcorp Research and Development, Burlington, NC, 27215, USA
| | - Michael Levandoski
- Labcorp Research and Development, Burlington, NC, 27215, USA
- Q2 Solutions, an IQVIA Business, Durham, NC, 27703, USA
| | - Brian Krueger
- Labcorp Research and Development, Burlington, NC, 27215, USA
- BaseX Scientific, LLC, Chapel Hill, NC, 27516, USA
| | | | - Deborah Boles
- Labcorp Research and Development, Burlington, NC, 27215, USA
| | - Melinda B Nye
- Labcorp Center for Esoteric Testing, Burlington, NC, 27215, USA
| | - Suzanne E Dale
- Labcorp Center for Esoteric Testing, Burlington, NC, 27215, USA
| | - Michael Sapeta
- Labcorp Center for Esoteric Testing, Burlington, NC, 27215, USA
| | | | | | | | - Oren Cohen
- Labcorp Drug Development, Burlington, NC, 27215, USA
- Fortrea Inc, Durham, NC, 27703, USA
| | - Stanley Letovsky
- Labcorp Center for Excellence in Data Science, AI and Bioinformatics, Burlington, NC, 27215, USA
| | - Lakshmanan K Iyer
- Labcorp Center for Excellence in Data Science, AI and Bioinformatics, Burlington, NC, 27215, USA.
| |
Collapse
|
2
|
Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, González Del Castillo J, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, García de Viedma D, Bouza E. COVID-19: On the threshold of the fifth year. The situation in Spain. REVISTA ESPANOLA DE QUIMIOTERAPIA : PUBLICACION OFICIAL DE LA SOCIEDAD ESPANOLA DE QUIMIOTERAPIA 2024; 37:17-28. [PMID: 38009431 PMCID: PMC10874674 DOI: 10.37201/req/123.2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Accepted: 11/17/2023] [Indexed: 11/28/2023]
Abstract
Despite having emerged from pandemic status, the incidence of COVID-19 episodes has recently increased in Spain, including pediatric cases and admissions to Intensive Care Units. Several recombinant variants are circulating among us, particularly XBB arising from two Omicron BA.2 sublineages with mutations in the genes encoding the spicule proteins that could increase binding to the ACE2 receptor and be more prone to immune escape. Faced with these, 3 pharmaceutical companies have developed vaccines adapted to the XBB.1.5 sublineage that are already available for administration in our setting with risks that should not be different from those of previous mRNA vaccines and with clearly favorable benefit/risk ratios. They should be applied to patients with potential for poor COVID-19 evolution and to collectives that have a particular relationship of proximity with them. Their application should be understood not only from a perspective of individual convenience but also from that of collective responsibility. The most convenient seems to be a simultaneous immunization of COVID-19 and influenza in our environment. In the therapeutic aspect, there is little to expect right now from antisera, but the already known antiviral drugs are still available and indicated, although their efficacy will have to be reevaluated due to their impact on populations that are mostly immunized and with a better prognosis than in the past. In our opinion, it is necessary to continue to make a reasonable and timely use of masks and other non-pharmacological means of protection.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - E Bouza
- Servicio de Microbiología Clínica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Marañón, Universidad Complutense. CIBERES. Ciber de Enfermedades Respiratorias. Madrid, Spain.
| |
Collapse
|
3
|
Peñas-Utrilla D, Muñóz P, Pérez-Lago L, García de Viedma D. Mining genomic repositories to further our knowledge of the extent of SARS-CoV-2 co-infections. Microb Genom 2024; 10:001158. [PMID: 38226969 PMCID: PMC10868610 DOI: 10.1099/mgen.0.001158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Accepted: 11/30/2023] [Indexed: 01/17/2024] Open
Abstract
Recombination events between Delta and Omicron SARS-CoV-2 lineages highlight the need for co-infection research. Existing studies focus on late-phase co-infections, with few examining earlier pandemic stages. This new study aims to globally identify and characterize co-infections using a bioinformatic pipeline to analyse genomic data from diverse locations and pandemic phases. Among 26988 high-quality SARS-CoV-2 isolates from 11 diverse project databases, we identified 141 potential co-infection cases (0.52%), surpassing previous prevalence estimates. These co-infections were observed throughout the pandemic timeline, with an increase noted after the emergence of the Omicron variant. Co-infections involving the Omicron variant were the most prevalent, potentially influenced by the high level of diversity within this lineage and its impact on the viral landscape. Additionally, we found co-infections involving the pre-Alpha/Alpha lineages, which have been rarely described, raising possibilities of contributing to new lineage emergence through recombination events. The analysis revealed co-infection cases involving both different and the same lineages/sublineages. Our study showcases the potential of our pipeline to leverage valuable information stored in global sequence repositories, advancing our understanding of SARS-CoV-2 co-infections. The prevalence of co-infections highlights the importance of monitoring viral diversity and its potential implications on disease dynamics. Integrating clinical data with genomic findings can further shed light on the clinical implications and outcomes of co-infections.
Collapse
Affiliation(s)
- Daniel Peñas-Utrilla
- Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
- Escuela de Doctorado, Universidad de Alcalá, Plaza de San Diego, s/n, 28801 Alcalá de Henares, Madrid, Spain
| | - Patricia Muñóz
- Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
- Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias-CIBERES, 28029 Madrid, Spain
- Departamento de Medicina, Universidad Complutense, Madrid, Spain
| | - Laura Pérez-Lago
- Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
| | - Darío García de Viedma
- Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
- Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias-CIBERES, 28029 Madrid, Spain
| |
Collapse
|